Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (TRAIL-R1) and tumor necrosis factor-related apoptosis-inducing ligand-receptor 2 (TRAIL-R2) are cell-surface receptors involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling. TRAIL-R1 and TRAIL-R2 genes have recently been mapped to chromosome 8p21-22, which is a frequent site of allelic deletions in many types of human tumors, including non-Hodgkin's lymphoma (NHL). Because TRAIL/TRAIL receptor system plays an important role in lymphocyte homeostasis, we hypothesized that the mutations of TRAIL-R1 and TRAIL-R2 may be involved in the development of NHL and that such mutations may be responsible for the allelic losses of 8p21-22 in NHL. In this study, we analysed the entire coding region of TRAIL-R2 gene and the death domain region of TRAIL-R1 gene for the detection of the somatic mutations in a series of 117 human NHLs using polymerase chain reaction (PCR)-based single strand conformation polymorphism (SSCP) analysis. Overall, eight tumors (6.8%) were found to have two TRAIL-R1 gene mutations or six TRAIL-R2 gene mutations. Interestingly, of the eight mutations, six missense mutations (two TRAIL-R1 and four TRAIL-R2) were detected in the death domains and one nonsense mutation of TRAIL-R2 was detected just before the death domain. Our data suggest that somatic mutations of TRAIL-R1 and TRAIL-R2 genes may play a role in the pathogenesis of some NHLs and that TRAIL-R1 and TRAIL-R2 genes might be the relevant genes to the frequent loss of chromosome 8p21-22 in human NHL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  • Arai T, Akiyama Y, Okabe S, Saito K, Iwai T and Yuasa Y. . 1998 Cancer Lett. 133: 197–204.

  • Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J and Tschopp J. . 2000 Nat. Cell Biol. 2: 241–243.

  • El-Naggar AK, Coombes MM, Batsakis JG, Hong WK, Goepfert H and Kagan J. . 1998 Oncogene 16: 2983–2987.

  • Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, Maeda Y, Tsuruta K, Miyaki M and Nakamura Y. . 1992 Cancer Res. 52: 5368–5372.

  • Fujiwar Y, Ohata H, Kuroki T, Koyama K, Tsuchiya E, Monden M and Nakamura Y. . 1995 Oncogene 10: 891–895.

  • Griffith TS, Chin WA, Jackson GC, Lynch DH and Kubin MZ. . 1998 J. Immunol. 161: 2833–2840.

  • Griffith TS and Lynch DL. . 1998 Curr. Opin. Immunol. 10: 559–563.

  • Grønbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K and Guldberg P. . 1998 Blood 92: 3018–3024.

  • Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E and Warnke RA. . 1994 Blood 84: 1361–1392.

  • Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, von Eschenbach AC and Troncoso P. . 1995 Oncogene 11: 2121–2126.

  • Keane MM, Ettenberg SA, Nau MM, Russell EK and Lipkowitz S. . 1999 Cancer Res. 59: 734–741.

  • Kim KH, Fisher MJ, Xu SQ, El-Deiry WS. . 2000 Clin. Cancer Res. 6: 335–346.

  • Lee JY, Dong SM, Kim SY, Yoo NJ, Lee SH and Park WS. . 1998 Virchows Arch. 433: 305–309.

  • Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Jang JJ, Han JY, Lee JY and Nam JY. . 1999a Cancer Res. 59: 5683–5686.

  • Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Pi JH, Lee HK, Kim HS, Jang JJ, Kim CS, Kim SH, Lee JY and Yoo NJ. . 1999b Cancer Res. 59: 3068–3072.

  • Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GS, Dong SM, Pi JH, Kim CS, Kim SH, Lee JY and Yoo NJ. . 1999c Oncogene 18: 3754–3760.

  • MacFarlane M, Ahmad M, Srinivasula SM, Fernades-Alnemri T, Cohen GM and Alnemri ES. . 1997 J. Biol. Chem. 272: 25417–25420.

  • MagGrogan D, Levy A, Bova GS, Isaacs WB and Bookstein R. . 1996 Genomics 35: 55–65.

  • Mariani SM and Krammer PH. . 1998a Eur. J. Immunol. 28: 1494–1498.

  • Mariani SM and Krammer PH. . 1998b Eur. J. Immunol. 28: 973–982.

  • Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godwski P and Ashkenazi A. . 1997 Curr. Biol. 7: 1003–1006.

  • Martinez-Lorenzo MJ, Alava MA, Gamen S, Kim KJ, Chuntharapal A, Pineiro A, Naval J and Anel A. . 1998 Eur. J. Immunol. 28: 2714–2725.

  • Mitelman F, Mertens F and Johansson B. . 1997 Nat. Genet. 15: 417–474.

  • Monni O, Joensuu H, Franssila K and Knuutila S. . 1996 Blood 87: 5269–5278.

  • Mori S, Murakami-Mori K, Nakamura S, Ashkenazi A and Bonavida B. . 1999 J. Immunol. 162: 5616–5623.

  • Nagata S. . 1997 Cell 88: 355–365.

  • Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM. . 1997 Science 276: 111–113.

  • Pai SI, Wu GS, Ozoren N, Wu L, Jen J, Sidransky D and El-Deiry WS. . 1998 Cancer Res. 58: 3513–3518.

  • Schneider P, Thome M, Burns K, Bodmer J-L, Hofmann K, Kataoka T, Holler N and Tschopp J. . 1997 Immunity 7: 831–836.

  • Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A. . 1997 Science 277: 818–821.

  • Shin MS, Park WS, Kim SY, Kanf SJ, Song KY, Park JY, Dong SM, Pi JH, Oh RR, Lee JY, Yoo NJ and Lee SH. . 1999 Am. J. Pathol. 154: 1785–1791.

  • Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M and Younes A. . 1997 Br. J. Haematol. 99: 618–624.

  • Thomas WD and Hersey P. . 1998 J. Immunol. 161: 2195–2220.

  • Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG and Rauch CT. . 1997 EMBO J. 16: 5386–5397.

  • Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, Mackay B, Minna JD and Gazdar AF. . 1999 Cancer Res. 59: 1973–1979.

  • Yaremko ML, Kutza C, Lyzak J, Mick R, Recant WM and Westbrook CA. . 1996 Genes Chromosomes Cancer 16: 189–195.

  • Zhang XD, Franco A, Myers K, Gray C, Nguyen T and Hersey P. . 1999 Cancer Res. 59: 2747–2753.

Download references

Acknowledgements

This work was supported by grant (No. 1999-2-20700-002-5) from the Basic Research Program of the Korea Science & Engineering Foundation.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, S., Shin, M., Kim, H. et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 20, 399–403 (2001). https://doi.org/10.1038/sj.onc.1204103

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204103

Keywords

This article is cited by

Search

Quick links